Table 1 Correlations between TPX2 expression in tissues and clinicopathologic characteristics of type 2 pRCC patients
From: TPX2 promotes papillary renal cell carcinoma progression by forming a ceRNA with LINC00894
Characteristics | TPX2 expression | P value | |
|---|---|---|---|
Low | High | ||
n | 40 | 39 | |
Gender, n (%) | 0.486 | ||
Male | 28 (35.4%) | 30 (38%) | |
Female | 12 (15.2%) | 9 (11.4%) | |
Age, mean ± sd | 58.7 ± 12.035 | 59.436 ± 11.534 | 0.782 |
BMI, median (IQR) | 25.15 (22.999, 27.298) | 24.251 (22.626, 26.598) | 0.468 |
Concomitant symptoms, n (%) | < 0.001 | ||
Yes | 12 (15.2%) | 27 (34.2%) | |
No | 28 (35.4%) | 12 (15.2%) | |
Tumor thrombus, n (%) | < 0.001 | ||
Yes | 6 (7.6%) | 29 (36.7%) | |
No | 34 (43%) | 10 (12.7%) | |
Maximum diameter of tumor, median (IQR) | 4.35 (2.925, 5.725) | 8.5 (5.5, 10.7) | < 0.001 |
T.stage, n (%) | < 0.001 | ||
≥ T3a | 11 (13.9%) | 29 (36.7%) | |
< T3a | 29 (36.7%) | 10 (12.7%) | |
N.stage, n (%) | < 0.001 | ||
N1 | 6 (7.6%) | 22 (27.8%) | |
N0 | 34 (43%) | 17 (21.5%) | |
M.stage, n (%) | 0.030 | ||
M1 | 3 (3.8%) | 10 (12.7%) | |
M0 | 37 (46.8%) | 29 (36.7%) | |
Fuhrman grading, n (%) | 0.001 | ||
1 | 3 (3.8%) | 0 (0%) | |
2 | 19 (24.1%) | 7 (8.9%) | |
3 | 18 (22.8%) | 26 (32.9%) | |
4 | 0 (0%) | 6 (7.6%) | |